시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 폐경 후 질 위축 치료 시장 보고서(2025년)
Postmenopausal Vaginal Atrophy Treatment Global Market Report 2025
상품코드 : 1769716
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,263,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,052,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,842,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

폐경 후 질 위축 치료 시장 규모는 향후 몇 년간 강력한 성장이 예상될 예정입니다. 요인으로는 갱년기 장애에 특화된 클리닉과 부인과 진찰 증가, 개별화된 환자별 치료에 대한 기호의 향상, 정부기관과 건강관련기관으로부터의 지원 강화, 라이프스타일과 의료개입 등 조기 폐경 발생 증가, 상용 약물 및 온라인 약국의 솔루션에 대한 액세스 확대 등이 포함됩니다. 예측 기간 동안 예상되는 주요 시장 동향으로는 선택적 에스트로겐 수용체 조절제(SERM)의 혁신, 디지털 건강 도구 및 원격 의료 서비스의 사용, 약물 전달 기술의 새로운 발전, 비호르몬 치료 전략의 진전, 최소 침습적 부인과 시술의 개선 등이 있습니다.

폐경 후 인구 증가는 향후 수년간 폐경 후 질 위축 치료 시장의 성장을 이끌 것으로 예측됩니다. 늘어남에 따라 더 많은 여성들이 오랫동안 살면서 폐경 후 단계에서 더 오랜 세월을 보낼 수 있습니다. 문질러지는 건조와 자극과 같은 증상을 완화하여 질의 건강을 촉진하고 전반적인 편안함과 행복감을 향상시킵니다. 예를 들어, 2022년 10월 메이요 클리닉에 따르면 2030년까지 전 세계 폐경 및 폐경 후 여성의 수는 12억 명에 달할 것으로 예상되며, 매년 약 4,700만 명의 여성이 이 단계에 진입할 것으로 예상됩니다. 이 인구층 증가가 시장의 확대에 크게 기여하고 있습니다.

폐경 후 질 위축 치료 시장에서 활동하는 기업들은 표적 증상 완화를 제공하고 호르몬 치료에 대한 순응도를 높이기 위해 에스트라디올 질 삽입물과 같은 혁신적인 솔루션에 집중하고 있습니다. 그리고 국소적으로 에스트로겐을 방출하고 갱년기 장애로 얇아진 질 조직의 회복을 돕습니다. Knight Therapeutics는 캐나다 시장에서 IMVEXXY를 출시했습니다. IMVEXXY의 독특한 소프트젤 제형은 빠른 용해를 보장하고 혈류로의 흡수를 최소화합니다. 이는 기존 에스트로겐 치료법에 비해 편리하고, 어플리케이터가 필요 없으며, 깔끔하게 사용할 수 있는 대안을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Postmenopausal vaginal atrophy treatment includes both medical and therapeutic methods aimed at relieving symptoms like vaginal dryness, irritation, and discomfort caused by decreased estrogen levels following menopause. The primary objective is to restore vaginal tissue health, increase moisture and elasticity, and support improved sexual and urinary function. These treatments play a crucial role in preventing complications and greatly enhancing overall quality of life.

The primary categories of postmenopausal vaginal atrophy treatments consist of estrogen-based drugs, non-estrogen-based drugs, and other alternatives. Estrogen-based therapies serve as hormone treatments for addressing menopausal symptoms, promoting reproductive wellness, treating hormone-responsive cancers, and supporting gender-affirming care. These drugs can be administered through various methods, including oral, intravaginal, and others, and are available via multiple distribution channels such as hospital pharmacies, online platforms, and retail pharmacies. The treatments are used in diverse fields including gynecology, sexual wellness, and general pharmaceuticals, and cater to various end-users such as hospitals, home care setups, specialty clinics, and more.

The postmenopausal vaginal atrophy treatment market research report is one of a series of new publications from The Business Research Company that provides detailed insights into market statistics, including the global size of the postmenopausal vaginal atrophy treatment industry, regional market shares, competitive landscape, detailed market segmentation, current trends, growth opportunities, and any additional data needed to succeed in the industry. This report offers a comprehensive overview and an in-depth evaluation of both present conditions and future prospects within the market.

The postmenopausal vaginal atrophy treatment market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Growth during the historical period has been influenced by factors such as a rising prevalence of postmenopausal symptoms, heightened awareness of vaginal health and menopause-related issues, an expanding global population of aging women, increased spending on women's healthcare, and a growing shift towards non-hormonal and localized treatment approaches.

The postmenopausal vaginal atrophy treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. Contributing to this future growth are factors such as a rising number of menopause-focused clinics and gynecological consultations, increasing preference for personalized and patient-specific therapies, enhanced backing from governmental and health-focused organizations, a growing occurrence of early menopause driven by lifestyle and medical interventions, and wider accessibility of over-the-counter and online pharmacy solutions. Prominent market trends projected for the forecast period include innovations in selective estrogen receptor modulators (SERMs), the use of digital health tools and telehealth services, new advancements in drug delivery technologies, progress in non-hormonal treatment strategies, and improvements in minimally invasive gynecological procedures.

The increasing postmenopausal population is expected to drive the growth of the postmenopausal vaginal atrophy treatment market in the coming years. This population includes women who have not had a menstrual period for 12 consecutive months, marking the end of their reproductive phase. As life expectancy rises, more women are living longer and spending additional years in the postmenopausal stage. Treatments for postmenopausal vaginal atrophy help relieve symptoms such as dryness and irritation caused by decreased estrogen levels, thereby promoting vaginal health and improving overall comfort and well-being. For example, according to the Mayo Clinic in October 2022, the number of menopausal and postmenopausal women worldwide is projected to reach 1.2 billion by 2030, with an estimated 47 million women entering this stage each year. This growing demographic is contributing significantly to the expansion of the market.

Companies operating in the postmenopausal vaginal atrophy treatment market are focusing on innovative solutions like estradiol vaginal inserts to deliver targeted symptom relief and enhance adherence to hormone therapy. These inserts are small devices placed in the vagina that release estrogen locally, aiding in the restoration of thinning vaginal tissues due to menopause. They provide effective relief from symptoms such as dryness, itching, and discomfort with minimal systemic absorption. For instance, in January 2024, Knight Therapeutics, a pharmaceutical company based in Canada, launched IMVEXXY in the Canadian market. This product is used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy associated with menopause. It delivers 4 mcg or 10 mcg of estradiol directly to vaginal tissues, supporting mucosal health and reducing pain during intercourse. IMVEXXY's unique softgel formulation ensures fast dissolution and minimal absorption into the bloodstream, offering a convenient, applicator-free, and mess-free alternative to traditional estrogen treatments. This innovation highlights the industry's dedication to developing patient-focused therapies that meet the specific needs of postmenopausal women.

In June 2023, Cosette Pharmaceuticals, a US-based pharmaceutical firm, acquired Intrarosa from Endoceutics Inc. for an undisclosed amount. This acquisition aims to enhance Cosette's women's health portfolio by incorporating a differentiated, patent-protected, commercially available product for the treatment of moderate-to-severe dyspareunia due to menopause. The move reinforces Cosette's commitment to women's health and expands its global reach, utilizing its commercial and manufacturing expertise to maintain patient access to Intrarosa. Endoceutics Inc. is a US-based provider of treatments for postmenopausal vaginal atrophy.

Major players in the postmenopausal vaginal atrophy treatment market are Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Novo Nordisk A/S, Viatris Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Mayne Pharma, Upsher-Smith Laboratories, Alvogen, Ligand Pharmaceuticals Incorporated, Dare Bioscience, Millicent Pharma Limited, TherapeuticsMD, and Bionovo Inc.

North America was the largest region in the postmenopausal vaginal atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in postmenopausal vaginal atrophy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postmenopausal vaginal atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The postmenopausal vaginal atrophy treatment market consists of revenues earned by entities by providing services such as medical consultation and diagnosis, hormonal therapy administration, patient education and counseling, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal vaginal atrophy treatment market also includes sales of vaginal gels, creams, tablets, patches, and rings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postmenopausal Vaginal Atrophy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postmenopausal vaginal atrophy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for postmenopausal vaginal atrophy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postmenopausal vaginal atrophy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Postmenopausal Vaginal Atrophy Treatment Market Characteristics

3. Postmenopausal Vaginal Atrophy Treatment Market Trends And Strategies

4. Postmenopausal Vaginal Atrophy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postmenopausal Vaginal Atrophy Treatment Growth Analysis And Strategic Analysis Framework

6. Postmenopausal Vaginal Atrophy Treatment Market Segmentation

7. Postmenopausal Vaginal Atrophy Treatment Market Regional And Country Analysis

8. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market

9. China Postmenopausal Vaginal Atrophy Treatment Market

10. India Postmenopausal Vaginal Atrophy Treatment Market

11. Japan Postmenopausal Vaginal Atrophy Treatment Market

12. Australia Postmenopausal Vaginal Atrophy Treatment Market

13. Indonesia Postmenopausal Vaginal Atrophy Treatment Market

14. South Korea Postmenopausal Vaginal Atrophy Treatment Market

15. Western Europe Postmenopausal Vaginal Atrophy Treatment Market

16. UK Postmenopausal Vaginal Atrophy Treatment Market

17. Germany Postmenopausal Vaginal Atrophy Treatment Market

18. France Postmenopausal Vaginal Atrophy Treatment Market

19. Italy Postmenopausal Vaginal Atrophy Treatment Market

20. Spain Postmenopausal Vaginal Atrophy Treatment Market

21. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market

22. Russia Postmenopausal Vaginal Atrophy Treatment Market

23. North America Postmenopausal Vaginal Atrophy Treatment Market

24. USA Postmenopausal Vaginal Atrophy Treatment Market

25. Canada Postmenopausal Vaginal Atrophy Treatment Market

26. South America Postmenopausal Vaginal Atrophy Treatment Market

27. Brazil Postmenopausal Vaginal Atrophy Treatment Market

28. Middle East Postmenopausal Vaginal Atrophy Treatment Market

29. Africa Postmenopausal Vaginal Atrophy Treatment Market

30. Postmenopausal Vaginal Atrophy Treatment Market Competitive Landscape And Company Profiles

31. Postmenopausal Vaginal Atrophy Treatment Market Other Major And Innovative Companies

32. Global Postmenopausal Vaginal Atrophy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postmenopausal Vaginal Atrophy Treatment Market

34. Recent Developments In The Postmenopausal Vaginal Atrophy Treatment Market

35. Postmenopausal Vaginal Atrophy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기